Dissemin is shutting down on January 1st, 2025

Published in

American Medical Association, JAMA Oncology

DOI: 10.1001/jamaoncol.2015.5570

Links

Tools

Export citation

Search in Google Scholar

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

Journal article published in 2016 by Nicholas D. James, Sarah J. Pirrie, Ann M. Pope, Darren Barton ORCID, Lazaros Andronis, Ilias Goranitis, Stuart Collins, Adam Daunton, Duncan McLaren, Joe O’Sullivan, Christopher Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Bony metastatic castrate-refractory prostate cancer (CRPC) has a poor prognosis and high morbidity. Zoledronic acid (ZA) is commonly combined with docetaxel in practice but lacks evidence that combining is effective, and strontium-89 (Sr89) is generally used palliatively in patients unfit for chemotherapy. Phase 2 analysis of the TRAPEZE trial confirmed combining the agents was safe and feasible, and the objectives of phase 3 include assessment of the treatments on survival.